There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling. Data on the pharmacokinetics of trazodone in children are currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30, 75, and 150 mg once a day (q.d.), respectively, were: (i) 2-to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d.; (ii) >6-to 12-year-old group, doses of 0.4, 1.0, and 1.9 mg/kg q.d.; (iii) >12-to 17-year-old group, doses of 0.4, 1.1, and 2.1 mg/kg q.d. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the aforementioned predicted dosing are currently in progress, and pharmacokinetic data obtained will enable further refinement of the PBPK models.
There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling. Data on the pharmacokinetics of trazodone in children are currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30, 75, and 150 mg once a day (q.d.), respectively, were: (i) 2-to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d.; (ii) >6-to 12-year-old group, doses of 0.4, 1.0, and 1.9 mg/kg q.d.; (iii) >12-to 17-year-old group, doses of 0.4, 1.1, and 2.1 mg/kg q.d. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the aforementioned predicted dosing are currently in progress, and pharmacokinetic data obtained will enable further refinement of the PBPK models.
Insomnia is a common sleep disorder in children with neurodevelopmental disorders (NDDs) such as autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), Down syndrome, and Rett Syndrome. [1] [2] [3] [4] Managing sleep disorders in children is critical both for the child and for the family, and it is often frustrating because of the refractory nature of the problem. 5 In children with NDDs, behavioral techniques for sleep induction may not be successful, thus requiring pharmacological interventions. 1, 6 However, because of the paucity of controlled clinical trials, medications for the treatment of pediatric insomnia in children with NDDs still represent an unmet medical need.
Trazodone exerts its antidepressant activity acting as serotonin antagonist and reuptake inhibitor. It is indicated primarily for the treatment of depression in patients who do not respond to antidepressants, such as selective serotonin reuptake inhibitors. 7 As a result of the combined serotoninergic receptor antagonism and serotonin reuptake inhibition, trazodone has demonstrated unique therapeutic flexibility, which has given rise to its potential use in a broad range of comorbidities of major depressive disorder as well as off-label indications, including insomnia. 8, 9 Trazodone also shows a sedating activity, with reviews indicating that insomnia is the most common reason for its off-label prescription and use in adult and pediatric populations. 8, 10 The hypnotic 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON TOPIC? ✔ Pediatric insomnia is a common comorbidity in neurodevelopmental disorders (NDDs). Although trazodone is frequently used for its ability to induce and maintain sleep in adults with depressive disorders, equivalent doses for children have not been defined. WHAT QUESTION DID THIS STUDY ADDRESS? ✔ This study aimed to predict the doses of trazodone to guide dosing in a clinical trial on pediatric insomnia in NDD. In addition, the interaction potential between trazodone and atomoxetine (frequently used in the treatment of attention deficit hyperactivity disorders) was predicted.
HOW DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ Pediatric doses of trazodone were predicted from commonly prescribed adult doses used in insomnia using a physiologically-based pharmacokinetic strategy. HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS? ✔ Currently there are no approved drugs for the treatment of pediatric insomnia in NDD. These predicted doses of trazodone were used to guide dosing in a pediatric investigational plan to address this need. Prediction of the lack of a potential drug-drug interaction between trazodone and atomoxetine suggests that these two drugs can be coadministered. effect of trazodone is promptly achieved, with possible beneficial effects on sleep architecture and quality in depressed patients. 10 Despite favorable anecdotal reports on the use of trazodone in pediatric insomnia, controlled clinical trials to evaluate its efficacy and safety and appropriate dosages in children are lacking. Currently, there are no clinical data on the pharmacokinetics (PK) or efficacy of trazodone in children, thus presenting challenges for the design of prospective clinical trials to evaluate the efficacy of this drug in children. The reliable prediction of relevant pediatric doses from known doses in adults is essential to support the conduct of prospective clinical trials in children.
Although the clinical PK of trazodone has been extensively studied in adults, [11] [12] [13] details relevant to the metabolism of trazodone remain unclear. In vitro studies have shown that it is metabolized predominantly by cytochrome P450 (CYP)3A4 and CYP3A5 to the active metabolite m-chlorophenylpiperazine (mCPP), 14 (A. Tolonen, unpublished data) with CYP2C19 and CYP2D6 contributing as well to trazodone metabolism into other (inactive) metabolites. Nevertheless, the fraction of the drug in vivo metabolized by CYP3A4 (fm CYP3A4 ) has not been quantified. Results from a study following the intravenous administration of 25 mg 14 C-trazodone in healthy volunteers suggested that mCPP formation accounts for at least 35% of trazodone dose. 15 However, once mCPP is formed, it undergoes extensive metabolism, 16 with clinical evidence confirming that the systemic exposure to mCPP in humans accounts for less than 5% of that of trazodone, on a molar basis, (R. Picollo, unpublished data) suggesting a minimal contribution by the metabolite to the pharmacological effect of the drug.
The aim of this study was to develop a physiologicallybased PK (PBPK) model for trazodone to estimate an appropriate starting dose for a phase II clinical study designed to evaluate the use of trazodone in the treatment of insomnia in children with ADHD. To our knowledge, this clinical study will be the first study with trazodone in children. In addition, the PK interaction potential between trazodone and atomoxetine (a drug commonly used to treat ADHD) would be predicted.
METHODS
Clinical studies were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice. Study protocols and informed consent documents were reviewed and approved by the relevant institutional review boards of the investigational centers. All study patients provided written informed consent.
PBPK modeling strategy
The Simcyp Population-Based Simulator (version 14, release 1; Simcyp Ltd, Sheffield, UK (Supplementary Information S4) was used for all simulations. The Simcyp Caucasian Healthy Volunteer population model was used for the adult simulations, whereas the Simcyp Pediatric population model was used for the simulations in children aged 2-6 years, >6-12 years, and >12-17 years. A PBPK model for trazodone was developed using in vitro and clinical data. The strategy adopted for modeling and simulations for predicting pediatric doses is summarized in Figure 1 .
Development of trazodone PBPK models
A PBPK model for trazodone was developed based on available physicochemical parameters, data from in vitro experiments, clinical PK parameters, and predicted parameters. Derivation of key parameters is described in the next sections. The final parameters used in the model are shown in Table 1 .
Estimation of CYP3A4-mediated metabolism for trazodone
Details of trazodone metabolic pathway are still lacking, although available evidence suggests that CYP3A4 is predominantly involved. In the absence of an accurate estimate of fm CYP3A4 , 100% was initially assumed. Initial simulations using the measured in vitro clearance of the unbound drug (CL int,u = 0.37 μL/min/pmol CYP3A4) 17 predicted a clearance of intravenously administered trazodone of 5.72 L/hour and an oral clearance of 7.47 L/hour compared with the observed values of 10 and 13 L/hour, respectively. 18 To fully recover the observed clearances, input parameters for CL int were back calculated from the observed clearance of intravenously administered trazodone using the well-stirred liver model (Eqs. 1 and 2). The CL int was then divided by average population values for liver weight (1,648 g), 19 ; mg protein/gram of liver (-39.8 mg protein/g liver) 20 and hepatic CYP enzyme abundance (137 pmol/mg for CYP3A4) 19 to give the CL int in units of µL/min/pmol P450.
where fu B is the fraction of unbound drug in blood (calculated from fraction of unbound drug in the plasma divided by the blood to plasma ratio -fu p /B:P); Q H is the blood flow in the hepatic vein (90 L/hour); CL R is the renal clearance (0 L/hour), and CL metH is the hepatic metabolic clearance. A CL int CYP3A4 of 0.438 µL/min/pmol was used in the model.
(2) CL metH = CL IV − CL R Figure 1 Summary of physiologically-based pharmacokinetic (PBPK) strategy for predicting the exposure of trazodone in children. CYP, cytochrome P450; DDI, drug-drug interaction; fm CYP3A4, CYP3A4 contribution.
Trazodone fm CYP3A4 was subsequently refined by assessing the inhibition effect of clarithromycin treatment on trazodone systemic exposures and comparing it to those observed in the clinical study. 21 This optimized fm CYP3A4 was further verified by assessing the inhibition effect of ritonavir treatment on trazodone systemic exposures. 22 Consequently, trazodone fm CYP3A4 was set to 70% in the final model. The balance of the metabolism (30%) was assigned as undefined human liver microsome metabolism in the PBPK model.
Estimation of trazodone absorption parameters
Trazodone oral solution and immediate release (IR) tablets were shown to be bioequivalent (A. Rusca, et al., unpublished data). Based on those findings, the first-order absorption model for the IR model was also used to describe the absorption kinetics of trazodone oral solution. In vitro data on the permeability of trazodone were used to predict the fraction absorbed (F a ) for the IR tablets (see Table 1 ) based on Eq. 3.
The F a was predicted to be 0.98, compared with the 0.72-0.91 that was previously reported. 18 A first-order absorption model was used to describe the absorption kinetics of trazodone extended release (ER) formulation. The absorption rate constant (k a ) was estimated from clinical data following a single oral dose of 300 mg ER 23 using the weighted least square algorithm and Nelder-Mead method. The initial estimate of k a was 0.1 hour −1 with a range of 0.01-2 hour −1 . The final k a estimate was 0.07 hour −1 .
Simulations for trazodone model development and verification in adults
To verify the developed trazodone model, simulated plasma concentrations were compared with observed clinical data for the following: CYP3A4 contribution (fm CYP3A4 = 100%) to the model was assessed by comparing the simulated drug-drug interaction (DDI) between a single 50 mg oral dose (IR) of trazodone (given on day 2) and clarithromycin (500 mg given at 24, 8, and 1 hour prior to and again at 8 hours after administration of trazodone to adult healthy volunteers) with clinical data (M. Zucconi, L. Olivieri and P. Dionisio, unpublished data). The Simcyp default model for clarithromycin was used for these simulations, and the performance of this model in recovering the observed CYP3A4 interaction has been verified by Ke et al. 25 The fm CYP3A4 value of 100% resulted in an overestimation of the DDI (see the Results section). Sensitivity analysis was used to optimise the fm CYP3A4 , resulting in a value of 70%. This refined trazodone model with fm CYP3A4 = 70% was further verified by simulating the DDI between a single 50 mg oral dose of trazodone (IR formulation that was administered on day 2) and ritonavir (200 mg twice a day (b.i.d.)) and comparing the PK to clinical data. 22 The Simcyp model for ritonavir (V15 release) was used for these simulations. Verification of the Study designs for all of the aforementioned simulations matched the corresponding clinical studies (Supplementary Information S1).
Trazodone model refinement for dose estimations in children Trazodone oral solution was the favored dosage form for the pediatric clinical study. Therefore, the final adult trazodone IR/oral solution model was used for the pediatric dose simulations using the age bands of 2-6 years, >6-12 years, and >12-17 years. Ten-by-ten trials of pediatric subjects (proportion of female = 0.5) in the respective age bands were generated. The prediction of dosage adjustment in children was based on matching the equivalent steadystate exposures (maximum plasma concentration (C max )) in adults following 30, 75-150 mg IR trazodone per day. Sensitivity analysis was used to determine the dose for each age band that resulted in a C max similar to that in adults, corresponding to the 30, 75, and 150 mg doses. For the treatment of sleeping disorders, the tested doses ranged from 30-90 mg/day (M. Zucconi, L. Olivieri and P. Dionisio, unpublished data). Therefore, 30 mg was selected to represent the lowest dose levels, and 75 mg was selected to represent an intermediate dosage between 60 and 90 mg. The approved doses for trazodone IR formulation in treating adult major depressive disorder is 150-400 mg/day, with an initial dose of 150 mg. 18 It was assumed that the F a and k a of trazodone relating to the oral solution are not age dependent. Preliminary simulations using the Simcyp mechanistic absorption module, i.e., the Advanced Dissolution, Absorption and Metabolism (ADAM) model, supported this assumption. 26 The pediatric ADAM module accounts for gastrointestinal physiological changes in the pediatric population, including gastric fluid volumes in fasted and fed states, intestinal surface area, intestinal fluid volumes, gastric emptying time, elevated gastric pH in early neonatal period, and so on. The lowest measured solubility for the hydrochloride salt of trazodone of 2.57 mg/mL was used as the intrinsic solubility input, with other formulation-specific parameters set to default Simcyp values for "solution with precipitation" formulation as a result of trazodone sparing solubility. Simulations supported an F a = 1.0. The systemic exposure of trazodone using the pediatric ADAM model was comparable to that simulated using the first-order absorption model. Further details are shown in Supplementary Information S2. Ongoing research will explore the ADAM model further.
In the absence of experimental data, the main plasma binding protein for trazodone was assumed to be albumin. The maturation pattern for albumin (HSA) and for α 1 -acid glycoprotein (AAG) are comparable in pediatric patients >2 years old. 27 Thus, the age effect on plasma protein binding of trazodone to either HSA or AAG is expected to be similar. The Simcyp CYP3A enzyme ontogeny was applied to the model, where 70% of trazodone metabolism was assigned to CYP3A4. Of the metabolism, 30% was assigned to undefined human liver microsome metabolism, and an ontogeny function was not applied.
Simulations to predict trazodone doses in children
A thorough QT/QTc study in adults confirmed the moderate effects of trazodone on the QT interval (distance between the Q and T waves on the electrocardiogram) and showed a weak correlation between QTc (QT corrected for heart rate) changes and maximum trazodone concentrations (A. Rusca, et al., unpublished data) . The pediatric dose projection in the 2-6, >6-12, and >12-17 age groups primarily focused on matching the equivalent steady-state C max in adults so as to minimize the potential risks of QT/QTc changes in the pediatric population. To reach this aim, the dose in pediatric subjects giving equivalent C max in adults were estimated using sensitivity analysis. The final simulated PK parameters and profiles following adult doses (IR formulation) of 30, 75, and 150 mg once a day (q.d.) were used.
The division of the pediatric population into the 2-6, >6-12, and >12-17 age groups was based on advice from the regulatory authority during discussions of the proposed clinical trial.
Atomoxetine model development
The development of a fit-for-purpose model for atomoxetine focused on the recovery of the clinically observed atomoxetine multiple-dose PK in CYP2D6 extensive metabolizers (EM) and poor metabolizers (PM) because the objective for model application was to assess drug interactions with trazodone as a victim drug.
Reported oral clearance values (estimated using population PK analysis) in CYP2D6 EMs and PMs 28 were used as clearance inputs. Initial simulations using the population PK analysis model estimated a volume of distribution (V ss ) of 0.85 L/kg, leading to an underestimation of atomoxetine C max in both EMs and PMs. Thus, the V ss was further optimized (V ss = 0.71 L/kg) based on the fitting of concentration-time profiles following the administration of 20 mg b.i.d. atomoxetine in CYP2D6 PMs. 29 The in vitro measured CYP3A4 concentration of trazodone required to produce half the maximum inhibition of CYP3A4 (K i ) 30 was verified by assessing the inhibition effect of atomoxetine treatment on midazolam (a CYP3A4 substrate) systemic exposure and comparing the predicted exposures with those clinically observed.
All input parameters used in the atomoxetine final model are presented in Table 2 .
Verification of atomoxetine model and application to DDI
The fit-for-purpose model for atomoxetine was verified by comparing the simulated profiles of atomoxetine 20 or 40 mg following b.i.d. administration in healthy CYP2D6 EMs and PMs with the observed clinical data. 28, 29 A sensitivity analysis was performed to verify the in vitro measured CYP3A4 K i 30 and the fraction of drug unbound in microsomes for atomoxetine using midazolam as a substrate. Details of the study designs and results of atomoxetine model verification are shown in Supplementary Information S3.
The verified atomoxetine model was then applied to prospectively predict the interaction between trazodone and atomoxetine. A total of 10 virtual trials of 10 subjects each (aged 20-50 years, proportion of female = 0.5) were generated.
Estimating Trazodone Dosage for Pediatric Insomnia
Oggianu et al.
Each subject received a single oral dose of 150 mg trazodone IR on day 10, 2 hours after the morning dose of atomoxetine (60 mg b.i.d. for 12 days). The dose staggering of 2 hours was selected based on matching the simulated time to reach maximum plasma concentration of trazodone (~ 0.5 hours) and atomoxetine (~ 2.5 hours) to maximize the extent of interaction.
Verification of the predictive performance of the PBPK models in this study
Predictive performance of the models were evaluated by the ratios of the predicted:observed PK parameters, such as area under the plasma concentration-time curve (AUC) and C max . Due to the potential variability in the clinical data and the more complex DDI mechanisms involved, model predictions were deemed to be acceptable when they were within 1.5-fold of the observed data. 31 In addition, predicted concentration-time profiles were compared with those observed in clinical studies (visual inspection).
RESULTS
Simulations of trazodone PK for single oral dose as 50 mg IR tablet or 30, 60, or 90 mg oral solution formulation in healthy adults PK parameters and concentration time profiles of the observed and simulated data for 50 mg IR tablet and 30, 60, or 90 mg oral solution formulation of trazodone in healthy adults are presented in Table 3 and Figure 2 . The AUC predicted/AUC observed and C max predicted/C max observed ratios were within 1.5-fold, thus indicating acceptable recovery of the clinical data by the trazodone PBPK model.
Simulations of the PK of 100 mg IR tablet of trazodone given three times a day for 7 days in healthy adults This simulation resulted in a mean C max of 1,822 ng/mL, compared with the clinically observed mean C max of 3,026 ng/mL. The predicted mean AUC 0-24 was 24,982 ng × hour/mL compared with a clinically observed value of 32,136 ng × hour/mL. The predicted/observed mean C max and AUC ratios were 0.60 and 0.78, respectively. The observed diurnal variation on trazodone PK following 100 mg IR three times a day (A. Nell, M. Burger, M.T. Rosignoli, R. Picollo and P. Dionisio, unpublished data) was not accounted for in the simulations. The slight underestimation of C max can probably be attributed to the absence of the diurnal variation in the model.
Simulation of trazodone interaction with clarithromycin
To verify trazodone fm CYP3A4 , the inhibitory effect of clarithromycin (dosed as 500 mg at 24, 8, and 1 hour prior to and again at 8 hours after administration of trazodone) on CYP3A4 and, consequently, on trazodone (single dose of 50 mg IR on day 2) systemic exposure was assessed. A fm-CYP3A4 of 100% in the base model led to an overestimation of the DDI. The predicted trazodone AUC and C max ratios were 2.77 and 1.45, respectively, compared with the observed ratios of 1.99 and 1.35, respectively. 21 Because of the uncertainty with the assumption of fm CYP3A4 = 100%, a sensitivity analysis of fm CYP3A4 was subsequently conducted, and a reduction of trazodone fm CYP3A4 to 70% allowed the recovery of the observed clarithromycin DDI data ( Table 3 ). The refined model, assuming fm CYP3A4 of 70%, generated predicted trazodone AUC and C max ratios of 2.09 and 1.28, respectively, consistent with the observed ratios of 1.99 and 1.35, respectively ( Table 3 ).
Simulation of trazodone interaction with ritonavir
Using the refined trazodone model with the optimized fm-CYP3A4, trazodone-predicted AUC and C max ratios were 3.14 and 1.39, respectively, compared with the observed ratios of 2.37 and 1.34, respectively ( Table 3) . Because the predicted ratios were within 1.5-fold of the observed ratios, this trazodone model was considered acceptable.
Predicted doses and PK parameters based on matching pediatric and adult C max to relevant adult doses
The final simulated C max , AUC, and concentration-time profiles corresponding to adult doses of 30, 75, and 150 mg IR q.d. are shown in Table 4 and Figure 3 .
Predicted doses in the following age groups, based on predicted exposures corresponding to adult dosages of 30, 75, and 150 mg q.d., respectively, were:
• For 2-to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d. 29 The predicted/observed ratios for C max and AUC were, respectively, 1.07 and 1.09 for EMs and 0.85 and 0.97 for PMs, indicating good recovery of the clinical data. Mean simulated C max and AUC values for atomoxetine 40 mg b.i.d. were 355 ng/mL and 2,025 ng × hour/mL, respectively, in CYP2D6 EMs and 1,608 ng/mL and 16,602 ng × hour/ mL, respectively, in PMs. The corresponding C max and AUC observed values were 527 ng/mL and 2,590 ng × hour/mL, respectively, in EMs and 1,949 ng/mL and 18,600 ng × hour/mL, respectively, in PMs. 28 The predicted/observed ratios for C max and AUC were, respectively, 0.67 and 0.78 for EMs and 0.83 and 0.89 for PMs, indicating acceptable recovery of clinical data, although C max was marginally underpredicted in EMs.
Simulation of the interaction between trazodone and atomoxetine
Estimations of DDI potential indicates that in CYP2D6 PMs, where the DDI magnitude is expected to be the most significant, trazodone AUC and C max predicted ratios were 1.06 and 1.05, respectively. In CYP2D6 EMs, trazodone AUC and C max predicted ratios were 1.01 and 1.01, respectively. These ratios indicate that an interaction between trazodone and atomoxetine is not likely to occur.
DISCUSSION
This PBPK study was designed to predict appropriate pediatric doses of trazodone for its use in a pediatric clinical trial. In the absence of clinical data on PK and efficacy of trazodone in children, this approach was essential for initial dose prediction that enabled ethical and regulatory approval for the clinical trial. Traditional allometric methods of dose prediction in children are frequently inaccurate because they are based on body weight (BW) changes without considering the impact of early childhood maturation in body composition, organ maturation, and ontogeny of eliminating enzymes, which are generally nonlinear with age. 32 Scaling by BW and body surface area or BW 0.75 were tested for 30 different drugs. The BW scaling method underpredicted the majority of doses across the pediatric range. The body surface area and BW 0.75 methods overpredicted some doses by up to 2.86-fold. 33 PBPK modeling was the method approved for dose prediction by the regulatory authority in this case because it has the potential to integrate information from age-specific physiological and biochemical data as well as data from preclinical, clinical, and in vitro sources to elucidate PK changes in children and complement pediatric studies and investigational plans. 34 The pediatric dose projection primarily focused on matching the equivalent steady-state C max in adults to minimize the potential risk of QT/QTc changes. However, corresponding AUCs were also evaluated and shown to be within the corresponding adult ranges. The developed and verified model for trazodone showed acceptable recovery of clinical data in the adult population prior to its application to the pediatric population for dose prediction.
Doses predicted in the following age groups for exposures corresponding to adult dosages of 30, 75, and 150 mg q.d., were:
• 2-to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d., respectively • >6-to 12-year-old group, doses of 0.4, 1.0, and 1.9 mg/ kg q.d., respectively • >12-to 17-year-old group, doses of 0.4, 1.1, and 2.1 mg/ kg q.d., respectively Based on these predictions, the following dosing strategy was adopted and approved by the regulator for a Pediatric Investigational Plan.
A total of children will be recruited in each of the age groups (2-6, >6-12, and >12-17 years) and stratified by age and dose level as follows:
• Arm 1: 0.25 mg/kg q.d. corresponding to 20 mg q.d. in adults • Arm 2: 0.4 mg/kg q.d. corresponding to 30 mg q.d. in adults • Arm 3: 0.5 mg/kg q.d. corresponding to 40 mg q.d. in adults.
The use of the doses predicted using PBPK modeling marked an important milestone toward the prospective testing of trazodone for insomnia in children. Data generated from the clinical trial based on these predicted doses will inform further model refinement in the future. The approach adopted for trazodone can be extended to other drugs where initial dosing in children presents a challenge.
Assumptions and limitations of the models are discussed. First, it is assumed that the pharmacodynamic effects of trazodone are equivalent with similar exposure in adults and children. No information is currently available to support the contrary. Although a key component of the trazodone model was a robust fm CYP3A4 parameter, data for a precise estimate of this parameter were unavailable. Based on in vitro data and relevant drug-interaction studies, an estimate of 70% was obtained for fm CYP3A4 . A mass balance study would be useful in obtaining a more accurate estimate for this parameter. CYP3A4 is the main enzyme contributing to the elimination of trazodone. The ontogeny profile of CYP3A4 showed that the hepatic CYP3A4 activity reached the adult level by the approximate age of 2 years. Therefore, the key factors that drove dose projection in the pediatric populations included age, body mass, liver size, liver blood flow, and plasma protein binding. The main plasma binding protein for trazodone was assumed to be albumin. However, the HSA and AAG are comparable in pediatric patients >2 years old. 27 Thus, the age effect on plasma protein binding of trazodone to either HSA or AAG is expected to be similar. A first-order absorption model was used in all of the pediatric simulations with the same adult k a and F a values based on the assumption that k a and F a of trazodone oral solution are not age dependent. Preliminary investigations using the ADAM model showed no age-dependent effect on F a and provided systemic exposure of trazodone comparable to that simulated from the first-order absorption model with the same adult k a and F a values.
Simulations of the trazodone interaction with atomoxetine indicated that no potential interaction is expected. Because atomoxetine is frequently used in NDDs, these predictions are reassuring and indicate that trazodone can be used concurrently with atomoxetine.
It can be concluded that the previously predicted doses of trazodone can be used to guide dosing in the initial clinical trials in pediatrics as endorsed by the European Medicines Agency (ref. EMEA-002142-PIP01-17), prior to conducting the first controlled clinical study in pediatrics. The conduct of a clinical trial in pediatrics is now in progress based on the previous dose predictions. Ethical and regulatory approvals for the clinical trial were based on the doses predicted in this analysis. PK data collection was recommended during the clinical trial for further verification of the doses and refinement of the PBPK models.
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